Evidence map›Paper›PMID 40452012›Full record

ArticleBMC cancer2025

The pan-immune-inflammation value predicts prognosis and chemotherapy-related adverse events in Wilms' tumor patients.

Kongkong Cui, Jie Lin, Peng Hong, Honggang Fang, Zaihong Hu, Zhiqiang Gao, Xiaomao Tian, Qinlin Shi, Guanghui Wei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kongkong CuiDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Jie LinDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Peng HongDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Honggang FangDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Zaihong HuDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Zhiqiang GaoDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Xiaomao TianDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China.
Qinlin ShiDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China. 485141@hospital.cqmu.edu.cn.
Guanghui WeiDepartment of Urology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Chongqing, China. ghwei1963@126.com.

Funding

China Postdoctoral Science Foundation 2022M720609National Natural Science Foundation of China 82302948
6 · The paper itself

Abstract

backgroundWilms' tumor (WT) is a common renal malignancy in children. Although certain patient groups exhibit high survival rates, those experiencing recurrence, metastasis, or chemoresistance face significant challenges. The identification of reliable prognostic markers is essential for adapting treatment strategies to enhance survival rates and reduce chemotherapy-related adverse events (CRAEs).

methodsThis study included patients diagnosed with WT at our institution. Inflammatory biomarkers were measured from pre-treatment blood tests, and their associations with event-free survival (EFS) and overall survival (OS) were evaluated using Kaplan-Meier and Cox regression analyses. The relationship between biomarkers and CRAEs was examined through logistic regression.

resultsMultifactorial Cox regression analysis identified tumor stage (HR = 4.68, 95% CI: 1.58-13.87, p = 0.005), pan-immune-inflammation value (PIV) (HR = 3.94, 95% CI: 1.80-8.60, p < 0.001), and neutrophil-to-lymphocyte ratio (NLR) (HR = 0.40, 95% CI: 0.18-0.90, p = 0.027) as independent prognostic factors for EFS. Multivariate Cox regression revealed that stage IV (HR = 12.24, 95% CI: 1.56-95.85, p = 0.017) and PIV levels exceeding 246.4 (HR = 5.50, 95% CI: 2.13-14.19, p < 0.001) were significant predictors for OS. Additionally, high PIV (OR 2.32, 95% CI: 1.15-4.67, p = 0.018) independently predicted the occurrence of CRAEs.

conclusionWT patients with higher PIV levels showed significant associations with poorer EFS, worse OS, and an increased likelihood of developing CRAEs during treatment.

Indexed as

Drug-Related Side Effects and Adverse ReactionsInflammationKidney NeoplasmsWilms TumorAdolescentBiomarkers, TumorChildChild, PreschoolFemaleHumansInfantKaplan-Meier EstimateMaleNeoplasm StagingNeutrophilsPrognosisBiomarkers, TumorChemotherapy-related adverse eventsNomogramOverall survivalRisk stratificationWilms tumor

Identifiers

PMID40452012
PMCPMC12128340

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.